Whitaker Myers Wealth Managers LTD. Buys New Stake in Johnson & Johnson (NYSE:JNJ)

Whitaker Myers Wealth Managers LTD. acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,129 shares of the company's stock, valued at approximately $308,000.

Other hedge funds have also added to or reduced their stakes in the company. Summit Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after acquiring an additional 61 shares during the period. Powers Advisory Group LLC raised its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after purchasing an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC raised its holdings in Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock worth $372,000 after purchasing an additional 63 shares during the last quarter. Knuff & Co LLC grew its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after buying an additional 64 shares during the period. Finally, Perkins Coie Trust Co grew its position in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock worth $600,000 after buying an additional 65 shares during the period. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 price objective on the stock. Royal Bank of Canada raised their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Finally, Barclays lowered their target price on Johnson & Johnson from $160.00 to $159.00 and set an "equal weight" rating for the company in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $173.27.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.07 on Tuesday, reaching $148.10. 11,094,063 shares of the company's stock traded hands, compared to its average volume of 8,798,511. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a 50-day simple moving average of $148.35 and a 200-day simple moving average of $156.11. The firm has a market cap of $356.57 billion, a PE ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.